Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

24 Applying Pharmacogenomics in Therapeutics
REFERENCES
1. American Association of Pharmaceutical Scientists. Pharmacogenomics (PGx). Available
from: http://www.aaps.org/Pharmacogenomics/ (accessed September 8, 2015).
2. Evans, W.E. and M.V. Relling. Pharmacogenomics: Translating functional genomics
into rational therapeutics. Science, 1999; 286(5439): 487–91.
3. Genomics and Its Impact on Science and Society: The Human Genome Project and
Beyond. U.S. Department of Energy Genome Research Programs. Available from:
www.genomics.energy.gov (accessed March 9, 2015).
4. Davaalkham, J., et al. Allele and genotype frequencies of cytochrome P450 2B6 gene
in a Mongolian population. Drug Metab Dispos, 2009; 37(10): 1991–93.
5. Dendukuri, N., et al. Testing for HER2-positive breast cancer: A systematic review and
cost-effectiveness analysis. CMAJ, 2007; 176(10): 1429–34.
6. Sheu, B.S., et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of
Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol
Ther, 2005; 21(3): 283–8.
7. Shi, S. and U. Klotz. Proton pump inhibitors: An update of their clinical use and pharmacokinetics.
Eur J Clin Pharmacol, 2008; 64(10): 935–51.
8. Zhang, L., et al. The effect of cytochrome P2C19 and interleukin-1 polymorphisms
on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole,
amoxycillin and clarithromycin in Chinese people. J Clin Pharm Ther, 2010;
35(6): 713–22.
9. Lawson, E.B., et al. Omeprazole limited sampling strategies to predict area under
the concentration-time curve ratios: Implications for cytochrome P450 2C19 and 3A
phenotyping. Eur J Clin Pharmacol, 2012; 68(4): 407–13.
10. Romkes, M., et al. Cloning and expression of complementary DNAs for multiple
members of the human cytochrome P450IIC subfamily. Biochemistry, 1991; 30(13):
3247–55.
11. Zaphiropoulos, P.G. RNA molecules containing exons originating from different
members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis
and liver. Nucleic Acids Res, 1999; 27(13): 2585–90.
12. Home Page of the Human Cytochrome P450 (CYP). Allele Nomenclature Committee,
2008. Available from: http://www.cypalleles.ki.se/ (accessed March 19, 2014).
13. de Morais, S.M., et al. The major genetic defect responsible for the polymorphism of
S-mephenytoin metabolism in humans. J Biol Chem, 1994; 269(22): 15419–22.
14. Blaisdell, J., et al. Identification and functional characterization of new potentially
defective alleles of human CYP2C19. Pharmacogenetics, 2002; 12(9): 703–11.
15. Baldwin, R.M., et al. Increased omeprazole metabolism in carriers of the CYP2C19*17
allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol, 2008;
65(5): 767–74.
16. Kim, M.J., et al. Effect of sex and menstrual cycle phase on cytochrome P450 2C19
activity with omeprazole used as a biomarker. Clin Pharmacol Ther, 2002; 72(2): 192–9.
17. Furuta, T., et al. Effect of genetic differences in omeprazole metabolism on cure
rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med, 1998;
129(12): 1027–30.
18. Furuta, T., et al. Effects of clarithromycin on the metabolism of omeprazole in relation
to CYP2C19 genotype status in humans. Clin Pharmacol Ther, 1999; 66(3): 265–74.
19. Sakai, T., et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors
in healthy subjects. Pharm Res, 2001; 18(6): 721–7.
20. Shirai, N., et al. Effects of CYP2C19 genotypic differences in the metabolism of
omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther, 2001; 15(12):
1929–37.